Suvemcitug
Based on 1 Customer Validation
Suvemcitug (APX-003) is a selective humanized rabbit monoclonal IgG1 (κ) anti-VEGF antibody. Suvemcitug inhibits the binding of VEGF to purified VEGFR1 (IC50 = 21.0 ng/mL) and VEGFR2 (IC50 = 275.4 ng/mL). Suvemcitug suppresses tumor angiogenesis, tumor growth and metastasis. Suvemcitug is applicable to research related to epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 96%
- CAS 番号: 1610010-57-5
- 分子量:145.782 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
VEGFR アイソフォーム固有の製品をすべて表示
More
生物活性
Human IgG1 kappa
Human
|
VEGFR1 21.0 ng/mL (IC50) |
VEGFR2 275.4 ng/mL (IC50) |
Suvemcitug potently inhibits the binding of VEGF to purified VEGFR1 (IC50 = 21.0 ng/mL) and VEGFR2 (IC50 = 275.4 ng/mL)[2].
Suvemcitug exhibits stronger anti-proliferative activity against umbilical vein endothelial cells than Bevacizumab (HY-P9906)[2].
Suvemcitug selectively binds to multiple VEGF isoforms (including VEGF164) and potently inhibits the binding of VEGF to VEGFR1 (IC50 = 21.0 ng mL-1) and VEGFR2 (IC50 = 275.4 ng mL-1) in cell-free biochemical assays[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Loaded Suvemcitug on ProA biosensor, can bind HY-P7420 VEGF121 Protein, Human (120a.a) with an affinity constant of 3.500E-11 M as determined in BLI assay.
化学情報
-
CAS 番号 1610010-57-5
-
性状 Liquid
-
分子量 145.782 kDa
-
Color Colorless to light yellow
-
SMILES
[Suvemcitug]
-
別名
APX-003; BD-0801
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Ma L, et al. Anti-PD-L1 envafolimab combined with anti-VEGF suvemcitug in pretreated solid tumors and hepatocellular carcinoma: an open-label phase II study with safety run-in stage. Invest New Drugs. 2025;43(2):181-190. [Content Brief]
[2]. Mao C, et al. Suvemcitug as second-line treatment of advanced or metastatic solid tumors and with FOLFIRI for pretreated metastatic colorectal cancer: phase Ia/Ib open label, dose-escalation trials. ESMO Open. 2023;8(3):101540. [Content Brief]
[3]. Yuan G, et al. Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial. Nat Cancer. 2026;7(1):182-193. [Content Brief]
[4]. Yuan G, et al. Suvemcitug plus chemotherapy for platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer: A phase 1b dose-escalation trial. Gynecol Oncol. 2024 Aug;187:212-220. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Suvemcitug 関連分類
HY-P990082 関連分類
Powered by Bioz
- Suvemcitug
- 1610010-57-5
- APX-003
- BD-0801
- APX003
- APX 003
- BD0801
- BD 0801
- BD-0801
- VEGFR
- VEGFA
- platinum-resistant epithelial ovarian cancer
- hepatocellular carcinoma
- platinum-resistant recurrent ovarian cancer
- VEGFR1/2
- tumor angiogenesis
- mouse VEGFA
- human VEGFA
- metastatic colorectal cancer
- human umbilical vein endothelial cells
- Inhibitor
- inhibitor
- inhibit